New drug candidates |
Composition |
Indications |
TargetBioMe search |
Pre-clinical study |
Clinical trial |
Remarks |
Microbiome-based biomarker |
LBP screening |
HEM 20-01 |
Single strain |
Depression |
|
US FDA phase 2 IND enabling in the second half of 2022 |
HEM 1036 |
Single strain |
Corolectal cancer syndrome (LARS) |
|
Initiation of phase 2 study in Australia in the second half of 2022 |
Indication exploration process in progress |
Anticancer drug-induced severe diarrhea |
|
Pilot study scheduled to be in 4Q of 2022 |
Cachexia |
|
HEM 1670, HEM 20-01 |
COPD |
|
HEM 792, HEM 382, HEM 224 |
NAFLD |
|
HEM 253, HEM 356, HEM 388 |
Childhood constipation |
|
intestinal disease |
FAP |
|
IBD |
|
Childhood autism |
|
Mental disease |
Pancreatic cancer |
|
Cancer |
Colon cancer |
|
Solid cancer |
|
Hematologic cancer |
|